Retatrutide 30mg

Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors. This triple agonism represents the next evolution beyond dual agonists like Tirzepatide, adding glucagon receptor activation to enhance energy expenditure and hepatic fat metabolism.

Early clinical trial data (Phase 2) demonstrated unprecedented results in body weight reduction and metabolic parameters, generating significant research interest. Retatrutide is currently in Phase 3 clinical trials conducted by Eli Lilly and represents one of the most anticipated compounds in the metabolic research pipeline.

Kyrolab stocks Retatrutide across 5 dosage variants from 10mg to 50mg with independent verification across 4 different suppliers — more cross-supplier verification than any other product in our catalogue.

⚗️ Purity Verification
TRIPLE-SUPPLIER VERIFIED:
WKC: 99.654% purity, 33.61mg actual — Janoshik #87698 (Key: 12CF7F5ML7PC)
Aurora: 99.803% purity, 35.33mg actual — Janoshik #89416 (Key: UQ4XVD5H9CNV). Batch: RT30N105P.
QST-Michelle: 99.710% purity, 31.45mg actual — Janoshik #82391 (Key: LXDZJZIV82B4)
Three independent tests, three suppliers, all 99.65%+.

Specifications

Molecular Weight	4626.22 g/mol
CAS	2381089-83-2
Receptor	Triple agonist: GLP-1R + GIPR + GCGR
Developer	Eli Lilly (Phase 3 trials)
Appearance	White lyophilised powder
Storage	2-8°C, protect from light
Dose	30mg per vial

⚗️ Research Use Only
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.